1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. Company
    AGEN   US00847G7051

AGENUS INC.

(AGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Agenus Inc.
Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. It is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.

Number of employees : 441 people.
Sales per Business
20202021Delta
License Fees and Milestones22.8625.9%220.0074.4% +862.51%
Non-cash Royalties47.5553.9%44.3615% -6.71%
Deferred Research and Development12.3014%22.367.6% +81.72%
Other services4.625.2%6.702.3% +45.14%
Research and Development0.750.9%1.480.5% +95.76%
Clinical Product--0.590.2%-
Deferred Grant0.090.1%0.180.1% +102.2%
USD in Million
Sales per region
20202021Delta
United States83.5594.8%288.9697.7% +245.85%
Rest of World4.625.2%6.702.3% +45.14%
USD in Million
Managers
Name Title Age Since
Garo H. Armen, Dr. Chairman & Chief Executive Officer 68 2019
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance 55 2019
Steven O’Day, Dr. Chief Medical Officer 60 2020
Craig Winter Chief Information Officer - -
Paulo Moreira Global Head-Clinical Operations - 2019
Julie DeSander Chief Business Officer - -
Andy Hurley Chief Commercial Officer - 2021
Alfred Dadson Chief Manufacturing Officer - 2019
Eric Humes Chief Quality Officer - 2022
Tracy Mazza Clemente Chief People Officer - -
Members of the board
Name Title Age Since
Garo H. Armen, Dr. Chairman & Chief Executive Officer 68 2019
Wadih Jordan Independent Director 86 2003
Brian J. Corvese Independent Director 64 2007
Ulf Arne Wiinberg Independent Director 62 2016
Timothy R. Wright Lead Independent Director 63 2009
Allison M. Jeynes-Ellis, Dr. Independent Director 55 2018
Susan B. Hirsch Independent Director 68 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 270,273,610 242,983,925 89.9% 0 0.0% 89.9%
Stock B 0 31,620 0 0.0% 0 0.0%
Shareholders
NameEquities%
The Vanguard Group, Inc. 17,830,122 6.93%
SSgA Funds Management, Inc. 17,758,624 6.91%
Deep Track Capital LP 15,229,187 5.92%
Incyte Corporation 12,070,195 4.69%
Gilead Sciences, Inc. 11,111,111 4.32%
Oracle Investment Management, Inc. 8,706,132 3.39%
BlackRock Fund Advisors 6,411,605 2.49%
Millennium Management LLC 5,732,026 2.23%
Invus Public Equities Advisors LLC 5,500,000 2.14%
Renaissance Technologies LLC 4,922,715 1.91%
Holdings
NameEquities%Valuation
MINK THERAPEUTICS, INC. (INKT) 26,332,958 78.5% 58,985,826 USD
Company contact information
Agenus, Inc.
3 Forbes Road
Lexington, MA 02421-7305

Phone : +1.781.674.4400
Fax : +1.781.674.4200
Web : http://www.agenusbio.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Agenus Inc.